MARKET

XOMA

XOMA

XOMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.90
+0.25
+1.01%
Closed 16:00 11/14 EST
OPEN
24.64
PREV CLOSE
24.65
HIGH
24.90
LOW
24.31
VOLUME
31.12K
TURNOVER
--
52 WEEK HIGH
24.90
52 WEEK LOW
11.02
MARKET CAP
217.93M
P/E (TTM)
-24.9199
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XOMA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XOMA News

  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.22h ago
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.1d ago
  • Will XOMA Continue to Surge Higher?
  • Zacks.1d ago
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.2d ago

More

Industry

Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
-0.27%

Hot Stocks

Name
Price
%Change

About XOMA

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
More

Webull offers XOMA Corp (XOMA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.